Type 1 Diabetes Mellitus Forecast in 12 Major Markets 2017-2027

Dublin, June 13, 2017 -- Research and Markets has announced the addition of the "Type 1 Diabetes Mellitus Forecast in 12 Major Markets 2017-2027" report to their offering.

Type 1 Diabetes Mellitus (T1DM) is a multisystem disease that progressively destroys the pancreas' ability to produce insulin. This leads to a chronic condition of defective metabolism of fat, carbohydrates and proteins due to the lack of insulin. It occurs mainly in childhood and adolescents, however a rising number of latent autoimmune diabetes of adulthood (LADA) cases have been reported mainly due to a better understanding and diagnosis of the disease.

This report provides the current prevalent population for Type 1 Diabetes Mellitus across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China and Russia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Type 1 Diabetes Mellitus have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

There are many co-morbidities associated with Type 1 Diabetes Mellitus, including:

- Chronic pancreatitis
- Cystic fibrosis
- Autoimmune disorders
- Hyperglycaemia
- Heart and blood vessel diseases (MI, Stroke, Atherosclerosis, Hypertension, Angina)
- Neuropathy
- Nephropathy (leading to CKD)
- Ulcerations
- Eye damage (retinopathy)
- Foot damage
- Ketoacidosis
- Lower limb amputation
- Skin/Mouth conditions
- Pregnancy complications

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key Comorbid Conditions/Features associated with the disease

8. Methodology for quantification of patient numbers

9. Top-line Prevalence for Type 1 Diabetes Mellitus

10. Features of Type 1 Diabetes Mellitus Patients
10.1 Comorbidities and Sequelae in T1DM Patients
10.2 T1DM patients with Retinopathy
10.3 Prevalence of T1DM defining antibodies

11. Abbreviations used in the report

12. Patient-Based Offering

13. Online Pricing Data and Platforms

14. References

15. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/d5sxfd/type_1_diabetes

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Endocrine and Metabolic Disorders Drugs